Gilead Sciences (GILD) Current Assets (2009 - 2026)
Gilead Sciences' (GILD) quarterly Current Assets came in at $18.6 billion in Q1 2026, up 10.3% YoY from $16.9 billion in Q1 2025, and up 1.63% on a QoQ basis from $18.3 billion in Q4 2025.
Gilead Sciences (GILD) Current Assets (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Current Assets data on file, last reported at $18.6 billion in Q1 2026.
- Quarterly Current Assets rose 10.3% year-over-year to $18.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.6 billion (up 10.3% YoY) and the FY2025 annual result came in at $18.3 billion, down 4.33% from the prior year.
- Current Assets grew to $18.6 billion in Q1 2026, from $18.3 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $19.2 billion in Q4 2024 to a low of $12.3 billion in Q2 2024.
- A 5-year average of $15.3 billion and a median of $14.7 billion in 2025 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets fell 13.79% — and 2025, when it gained 20.94%.
- Tracing GILD's Current Assets over 5 years: stood at $14.4 billion in 2022, then rose by 11.37% to $16.1 billion in 2023, then gained by 19.2% to $19.2 billion in 2024, then declined by 4.33% to $18.3 billion in 2025, then grew by 1.63% to $18.6 billion in 2026.
- The last three Current Assets figures came in at $18.6 billion (Q1 2026), $18.3 billion (Q4 2025), and $17.9 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 23.56 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 36.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.95 Bn |
| Mar 31, 2026 | 18.64 Bn |
| Dec 31, 2025 | 18.34 Bn |
| Sep 30, 2025 | 17.87 Bn |
| Jun 30, 2025 | 14.72 Bn |
| Mar 31, 2025 | 16.90 Bn |
| Dec 31, 2024 | 19.17 Bn |
| Sep 30, 2024 | 14.78 Bn |
| Jun 30, 2024 | 12.32 Bn |
| Mar 31, 2024 | 14.04 Bn |
| Dec 31, 2023 | 16.09 Bn |
| Sep 30, 2023 | 15.98 Bn |
| Jun 30, 2023 | 14.29 Bn |
| Mar 31, 2023 | 13.46 Bn |
| Dec 31, 2022 | 14.44 Bn |
| Sep 30, 2022 | 13.55 Bn |
| Jun 30, 2022 | 13.18 Bn |
| Mar 31, 2022 | 12.63 Bn |
| Dec 31, 2021 | 14.77 Bn |
| Sep 30, 2021 | 13.99 Bn |